LIPOSCIENCE COLLABORATES WITH A LEADING ACADEMIC MEDICAL CENTER TO IDENTIFY RISK FACTORS AIMED AT IMPROVING MANAGEMENT OF ACUTE CORONARY SYNDROME
RALEIGH, N.C. – January 09, 2013 – LipoScience, Inc., an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases, today announced that it has entered into a research agreement with Duke University School of Medicine. The research will be aimed at identifying cardiovascular risk factors that can be used alone or in combination with other clinical
measures to improve stratification and management of acute coronary syndrome. The agreement encompasses studies to be performed with Duke’s CATHGEN (CATHeterizationGENetics) and other patient registries.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.